Pharmacokinetic studies of ambenonium chloride in patients with myasthenia gravis

Serum levels of ambenonium chloride (AC) were monitored in 4 myasthenic patients. This determination revealed important intraindividual variations (up to 10-fold) over a period of 24 h. Levels varied considerably between different patients (maximum serum concentration of ambenonium chloride ranged f...

Full description

Saved in:

Bibliographic Details
Published in:	European journal of drug metabolism and pharmacokinetics Vol. 16; no. 4; pp. 299 - 303
Main Authors:	THARASSE-BLOCH, C, CHABENAT, C, BOUCLY, P, MARCHAND, J, ELKHARRAT, D, BOUCLY-GOESTER, C, GAJDOS, P
Format:	Journal Article
Language:	English
Published:	Genève Médecine et hygiène 01-10-1991
Subjects:	Administration, Oral Adult Aged Aged, 80 and over Ambenonium Chloride - blood Ambenonium Chloride - pharmacokinetics Biological and medical sciences Biological Availability Female Humans Male Medical sciences Muscle Myasthenia Gravis - metabolism Pharmacology. Drug treatments Quaternary ammonium compound Human Nervous system diseases Myasthenia gravis Oral administration Anticholinesterase agent Pharmacokinetics
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Serum levels of ambenonium chloride (AC) were monitored in 4 myasthenic patients. This determination revealed important intraindividual variations (up to 10-fold) over a period of 24 h. Levels varied considerably between different patients (maximum serum concentration of ambenonium chloride ranged from 0.129 to 0.812 micrograms/ml) and no correlation between the daily dose and the AUC was found. These characteristic properties of ambenonium chloride could explain the erratic pattern of bioavailability observed as well as the difficulty in controlling the disease in some patients.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	0378-7966 2107-0180
DOI:	10.1007/BF03189975